Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Acadia Pharmaceutica (ACAD)

Acadia Pharmaceutica (ACAD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Acadia Pharmaceutica 3611 VALLEY CENTRE DRIVE SUITE 300 SAN DIEGO CA 92130 USA

P: 858-558-2871 F: 858-212-0513

Description:

Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.

Key Statistics

Overview:

Market Capitalization, $K 2,721,293
Shares Outstanding, K 160,643
Annual Sales, $ 441,760 K
Annual Net Income, $ -281,580 K
Last Quarter Sales, $ 115,220 K
Last Quarter Net Income, $ -43,870 K
60-Month Beta 0.66
% of Insider Shareholders 28.50%
% of Institutional Shareholders 91.18%
Float, K 114,860
% Float 71.50%

Growth:

1-Year Return -57.53%
3-Year Return -18.40%
5-Year Return -46.75%
5-Year Revenue Growth 736,166.69%
5-Year Earnings Growth -9.82%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.27 on 08/04/21
Next Earnings Date N/A
Earnings Per Share ttm -1.65
EPS Growth vs. Prev Qtr 35.71%
EPS Growth vs. Prev Year 0.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

ACAD Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -10.13
Price/Earnings to Growth N/A
Return-on-Equity % -43.11%
Return-on-Assets % -34.24%
Profit Margin % -63.74
Net Margin % 32.45
Debt/Equity 0.00
Price/Sales 6.32
Price/Cash Flow N/A
Price/Book 4.77
Book Value/Share 3.52
Interest Coverage 0.00
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar